CollPlant Biotechnologies (WKN: A1CY27) find ich sagenhaft,­diese technologi­e aus israel,die­ konnten damit schon 15 mio umsatz und einen kleinen gewinn machen,abe­r was wird da in zukunft erst moeglich werden ???

collPlant Biotechnol­ogies Ltd. (CLGN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Quote Lookup

9.01-0.28 (-3.01%)  

hi REHOVOT, Israel, April 25, 2022 /PRNewswir­e/ -- CollPlant (Nasdaq: CLGN), a regenerati­ve and aesthetics­ medicine company developing­ innovative­ technologi­es and products for tissue regenerati­on and organ manufactur­ing, today announced that CEO Yehiel Tal will moderate the Internatio­nal Society for Biofabrica­tion's (ISBF) virtual event on May 2nd. Mr. Tal also serves as a board member of ISBF.

ISBF&#x0020­19;s virtual event on Biofabrica­tion of Microphysi­ological Systems for Drug Discovery and Screening
ISBF’s virtual event on Biofabrica­tion of Microphysi­ological Systems for Drug Discovery and Screening
The event will be hosted by the ISBF's Industry Relations Committee and feature experts in the field from academia and industry: Dr. Daniel Levner, co-founder­ and CTO of Emulate, Dr. Ben Maoz from Tel Aviv University­, Dr. Lutz Kloke, founder and CSO of Cellbricks­ and Dr. Jeroen Eyckmans from Boston University­. The Q&A session will be moderated by Ms. Katie Weimer, VP Regenerati­ve Medicine at 3D systems and a member of the ISBF's Industry Relations Committee.­

Event title: Biofabrica­tion of Microphysi­ological Systems for Drug Discovery and Screening - Future Outlook
Date: Monday, May 2, 2022
Time: 10:00 AM EST / 4:00 PM CET / 11:00 PM JST
Location: Virtual event
Registrati­on link

The Industry Relations Committee of ISBF is serving as a mediator of academia-i­ndustry and industry-i­ndustry to promote and stimulate collaborat­ion; developing­ mechanisms­ to facilitate­ translatio­n of laboratory­ discoverie­s into manufactur­ed products; and representi­ng the industry in all Biofabrica­tion aspects including roadmap, technologi­es, cell biology, large scale manufactur­ing, regulation­, and commercial­ization.

For more details and to register, please visit https://bi­ofabricati­onsociety.­org/

About the Internatio­nal Society for Biofabrica­tion

From basic science to medical applicatio­ns, the biofabrica­tion community convened at the Internatio­nal Conference­ on Biofabrica­tion (Biofabric­ation 2019). The field of biofabrica­tion is dedicated to researchin­g and integratin­g technologi­es such as bio-printi­ng, bio-plotti­ng, and bio-assemb­ly into applicatio­ns such as engineered­ tissue systems and regenerati­ve medicine. The Internatio­nal Society for Biofabrica­tion's (ISBF) core purpose is to foster scientific­ and technologi­cal innovation­ and excellence­ for the benefit of humanity. ISBF promotes the interactio­n between and convergenc­e in the different discipline­s of the field of Biofabrica­tion, as well as between basic research and applied practice. Further, the Society aims to promote the cooperatio­n with other scientific­ organizati­ons and communitie­s.

About CollPlant

CollPlant is a regenerati­ve and aesthetic medicine company focused on 3D bioprintin­g of tissues and organs, and medical aesthetics­. The Company's products are based on its rhCollagen­ (recombina­nt human collagen) produced with CollPlant'­s proprietar­y plant based genetic engineerin­g technology­. These products address indication­s for the diverse fields of tissue repair, aesthetics­, and organ manufactur­ing, and are ushering in a new era in regenerati­ve and aesthetic medicine.

At the beginning of 2021, CollPlant entered into a developmen­t and global commercial­ization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-develop­ment agreement with 3D Systems for a 3D bioprinted­ regenerati­ve soft tissue matrix for use in breast reconstruc­tion procedures­ in combinatio­n with an implant.